We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Impath Clients to Benefit from Cell Analysis' QCA System

By HospiMedica staff writers
Posted on 16 Apr 2004
Under the terms of a recently announced agreement, the Quantitative Cellular Assessment (QCA) system of Cell Analysis (Evanston, IL, USA) will be provided exclusively to the clients of Impath, Inc. More...
(New York, NY, USA). Terms were not disclosed.

The QCA system has been cleared by the U.S. Food and Drug Administration (FDA) for estrogen receptor (ER) markers in breast cancer and is awaiting clearance for the oncoprotein Her2/neu. In addition, the system has been designed to analyze all nuclear, membranous, and cytoplasmic immunohistochemical (IHC) markers. The QCA system objectively analyzes tumor cells for predictive and prognostic markers using quantitative image analysis of nuclear and membrane antigens, enabling more precise, targeted therapeutic decision-making.

"QCA is an important new technology that can help improve the quality of information available to pathologists, researchers, and oncologists, so they can make the best decisions for their patients,” explained Joel Herm, CEO of Cell Analysis. The company is a privately held life sciences company that is developing affordable, easy-to-use image analysis tools for studying cancer cells.

"Cell Analysis' QCA system and built-in control of IHC stained tissue slides facilitate reproducibility and rapid turnaround while removing the clinician's perceived limitation of manual inspection,” said Carter H. Eckert, chairman and CEO of Impath. The company states it is in the business of improving outcomes for cancer patients. Its Physician Services uses sophisticated technologies to provide patient-specific cancer diagnostics and prognostic services to pathologists and oncologists.




Related Links:
Impath
Cell Analysis

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Hematology Consumables
Bioblood Devices
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.